吸入性过敏免疫治疗临床实践指南执行摘要
该指南由耳鼻咽喉头颈外科学会制定,针对5岁及以上过敏性鼻炎伴或不伴过敏性哮喘患者,提出免疫治疗的质量改进建议。指南包含1条强推荐和多项推荐与选项,涵盖适应症、禁忌症、患者教育、给药方案及疗程等。
要点
- 进行过敏皮肤试验或施用免疫治疗的临床医生必须能够诊断和处理过敏反应(强推荐)。
- 对药物治疗或过敏原回避控制不佳或偏好免疫调节的过敏性鼻炎患者,应提供或转诊进行免疫治疗。
- 免疫治疗疗程至少3年,持续时长依据患者治疗反应而定。
核心结论
- 指南旨在识别质量改进机会,为吸入性过敏免疫治疗管理提供可信的循证推荐,优化患者护理、促进安全有效治疗、减少不合理的医疗差异并降低伤害风险。
研究设计与样本
- 指南制定小组针对5岁及以上过敏性鼻炎伴或不伴过敏性哮喘、为免疫治疗候选或正在接受免疫治疗的患者制定临床实践指南,目标受众为所有参与免疫治疗施用的临床医生。
主要发现
- 指南制定小组做出1条强推荐(关键行动声明10),并对关键行动声明1、2A、3、4、5、6、7、9、11、12做出推荐。
- 指南制定小组将关键行动声明2B和8作为选项提供。
关键数值与推荐
- 关键行动声明10(强推荐):进行过敏皮肤试验或施用免疫治疗的临床医生必须能够诊断和处理过敏反应。
- 关键行动声明1(推荐):对药物治疗或过敏原回避或两者控制不佳、或偏好免疫调节的过敏性鼻炎伴或不伴过敏性哮喘患者,临床医生应提供或转诊至能提供免疫治疗的临床医生。
- 关键行动声明2A(推荐):对妊娠、未控制哮喘或无法耐受注射肾上腺素的患者,临床医生不应启动免疫治疗。
- 关键行动声明12(推荐):对免疫治疗症状控制中的患者,临床医生应治疗至少3年,持续治疗时长基于患者对治疗的反应。
- 关键行动声明2B(选项):对使用伴随β受体阻滞剂、有过敏反应史、存在全身免疫抑制或嗜酸性食管炎(仅舌下免疫治疗)的患者,临床医生可选择不启动免疫治疗。
临床怎么用
- 临床医生应为符合条件的过敏性鼻炎患者提供或转诊进行免疫治疗,并在启动前评估哮喘症状及控制情况。
- 临床医生应教育免疫治疗候选患者关于皮下免疫治疗与舌下免疫治疗(水剂和片剂)在风险、获益、便利性和费用方面的差异。
- 临床医生应告知患者免疫治疗在预防新过敏原致敏、降低发生过敏性哮喘风险及改变疾病自然病程方面的潜在获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Allergen immunotherapy (AIT) is the therapeutic exposure to an allergen or allergens selected by clinical assessment and allergy testing to decrease allergic symptoms and induce immunologic tolerance. Inhalant AIT is administered to millions of patients for allergic rhinitis (AR) and allergic asthma (AA) and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). Despite its widespread use, there is variability in the initiation and delivery of safe and effective immunotherapy, and there are opportunities for evidence-based recommendations for improved patient care. PURPOSE: The purpose of this clinical practice guideline is to identify quality improvement opportunities and provide clinicians trustworthy, evidence-based recommendations regarding the management of inhaled allergies with immunotherapy. Specific goals of the guideline are to optimize patient care, promote safe and effective therapy, reduce unjustified variations in care, and reduce risk of harm. The target patients for the guideline are any individuals aged 5 years and older with AR, with or without AA, who are either candidates for immunotherapy or treated with immunotherapy for their inhalant allergies. The target audience is all clinicians involved in the administration of immunotherapy. This guideline is intended to focus on evidence-based quality improvement opportunities judged most important by the guideline development group. It is not intended to be a comprehensive, general guide regarding the management of inhaled allergies with immunotherapy. The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients. ACTION STATEMENTS: The guideline development group made a strong recommendation that (Key Action Statement [KAS] 10) the clinician performing allergy skin testing or administering AIT must be able to diagnose and manage anaphylaxis. The guideline development group made recommendations for the following KASs: (KAS 1) Clinicians should offer or refer to a clinician who can offer immunotherapy for patients with AR with or without AA if their patients' symptoms are inadequately controlled with medical therapy, allergen avoidance, or both, or have a preference for immunomodulation. (KAS 2A) Clinicians should not initiate AIT for patients who are pregnant, have uncontrolled asthma, or are unable to tolerate injectable epinephrine. (KAS 3) Clinicians should evaluate the patient or refer the patient to a clinician who can evaluate for signs and symptoms of asthma before initiating AIT and for signs and symptoms of uncontrolled asthma before administering subsequent AIT. (KAS 4) Clinicians should educate patients who are immunotherapy candidates regarding the differences between SCIT and SLIT (aqueous and tablet) including risks, benefits, convenience, and costs. (KAS 5) Clinicians should educate patients about the potential benefits of AIT in (1) preventing new allergen sensitization, (2) reducing the risk of developing AA, and (3) altering the natural history of the disease with continued benefit after discontinuation of therapy. (KAS 6) Clinicians who administer SLIT to patients with seasonal AR should offer pre- and co-seasonal immunotherapy. (KAS 7) Clinicians prescribing AIT should limit treatment to only those clinically relevant allergens that correlate with the patient's history and are confirmed by testing. (KAS 9) Clinicians administering AIT should continue escalation or maintenance dosing when patients have local reactions to AIT. (KAS 11) Clinicians should avoid repeat allergy testing as an assessment of the efficacy of ongoing AIT unless there is a change in environmental exposures or a loss of control of symptoms. (KAS 12) For patients who are experiencing symptomatic control from AIT, clinicians should treat for a minimum duration of 3 years, with ongoing treatment duration based on patient response to treatment. The guideline development group offered the following KASs as options: (KAS 2B) Clinicians may choose not to initiate AIT for patients who use concomitant beta-blockers, have a history of anaphylaxis, have systemic immunosuppression, or have eosinophilic esophagitis (SLIT only). (KAS 8) Clinicians may treat polysensitized patients with a limited number of allergens.
引用
- Gurgel RK, Baroody FM, Damask CC, et al. Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy. Otolaryngol Head Neck Surg. 2024. PMID: 38408153. doi:10.1002/ohn.650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。